Skip to main content

Tipp

Weitere Artikel dieser Ausgabe durch Wischen aufrufen

Erschienen in: Wiener klinische Wochenschrift 1-2/2021

02.09.2020 | original article

HS-173, a selective PI3K inhibitor, induces cell death in head and neck squamous cell carcinoma cell lines

verfasst von: MD Elisabeth Foki, MD Isabella Stanisz, MD Lorenz Kadletz, MD Ulana Kotowski, MD, DMD, MSc, MBA Rudolf Seemann, MD Rainer Schmid, MD, PD Gregor Heiduschka

Erschienen in: Wiener klinische Wochenschrift | Ausgabe 1-2/2021

Einloggen, um Zugang zu erhalten
share
TEILEN

Summary

Background

The selective PI3K (Phosphatidylinositol 3-kinase) inhibitor HS-173 has anticancer activity in non-small cell lung cancer and pancreatic cancer cells. Of all head and neck squamous cell carcinomas (HNSCC) 20% harbor specific mutations in the genome. The aim of this study was to investigate the effect of HS-173 on HNSCC cell lines.

Methods

The cell lines SCC25, CAL27 and FaDu were incubated with HS-173. Its antiproliferative effect was determined using the CCK‑8 cell proliferation assay. Combined incubation with cisplatin was performed and combination index analysis was conducted. To investigate its effect on radiotherapy, cells were irradiated with 2, 4, 6 and 8 Gy, respectively. Synergistic effects of radiation and HS-173 were measured by proliferation assays and clonogenic survival.

Results

The use of HS-173 induced significant reduction of cell proliferation across all cell lines. Most interestingly, it showed a synergistic effect with cisplatin treatment. Clonogenic survival revealed a radiosensitizing effect in CAL27 and FaDu cells. The HS-173 caused significant induction of apoptosis in SCC25 and FaDu cells.

Conclusion

The selective PI3K inhibitor HS-173 is a potent chemosensitizing and also radiosensitizing drug in treatment of HNSCC cell lines and could be an effective treatment in PI3K-mutated HNSCC.
Literatur
1.
Zurück zum Zitat Haddad RI, Shin DM. Recent advances in head and neck cancer. N Engl J Med. 2008;359:1143–54. CrossRef Haddad RI, Shin DM. Recent advances in head and neck cancer. N Engl J Med. 2008;359:1143–54. CrossRef
4.
Zurück zum Zitat Vermorken JB, Mesia R, Riviera F, et al. Platinum-based chemotherapyplus cetuximab in head and neck cancer. N Engl J Med. 2008;359:1116–27. CrossRef Vermorken JB, Mesia R, Riviera F, et al. Platinum-based chemotherapyplus cetuximab in head and neck cancer. N Engl J Med. 2008;359:1116–27. CrossRef
10.
Zurück zum Zitat Michmerhuizen NL, et al. Rationale for using irreversible EGFR-Growth Factor Inhibitors in combination with Phosphatidylinositol3-kinase Inhihitors for advanced head and neck squamous cell carinoma. Mol Pharmacol. 2019;95(5):528–36. CrossRef Michmerhuizen NL, et al. Rationale for using irreversible EGFR-Growth Factor Inhibitors in combination with Phosphatidylinositol3-kinase Inhihitors for advanced head and neck squamous cell carinoma. Mol Pharmacol. 2019;95(5):528–36. CrossRef
11.
Zurück zum Zitat Barretina J, Caponigro G, Stransky N, Venkatesan K, Margolin AA, Kim S, et al. The cancer cell line encyclopedia enables predictive modelling of anticancer drug sensitivity. Nature. 2012;483:603–7. CrossRef Barretina J, Caponigro G, Stransky N, Venkatesan K, Margolin AA, Kim S, et al. The cancer cell line encyclopedia enables predictive modelling of anticancer drug sensitivity. Nature. 2012;483:603–7. CrossRef
16.
Zurück zum Zitat Kean B, Kim S, Ahn Y. In vitro anticancer activity of PI3K alpha selective inhibitor BYL719 in head and neck cancer. Anticancer Res. 2015;35:175–82. Kean B, Kim S, Ahn Y. In vitro anticancer activity of PI3K alpha selective inhibitor BYL719 in head and neck cancer. Anticancer Res. 2015;35:175–82.
17.
Zurück zum Zitat Yang J, Nie J, Ma X, Wei Y, Peng Y, Wei X. Targeting PI3K in cancer. Mechanisms and advances in clinical trials. Mol Cancer. 2019;28:26. CrossRef Yang J, Nie J, Ma X, Wei Y, Peng Y, Wei X. Targeting PI3K in cancer. Mechanisms and advances in clinical trials. Mol Cancer. 2019;28:26. CrossRef
19.
Zurück zum Zitat Almasan A, Smith M, Hill B, Madanat Y. Idelalisib therapy of indolent B‑cell malignancies: chronic lymphocytic leukemia and small lymphocytic or follicular lymphomas. Blood Lymphat Cancer. 2016;6:1–6. PubMedPubMedCentral Almasan A, Smith M, Hill B, Madanat Y. Idelalisib therapy of indolent B‑cell malignancies: chronic lymphocytic leukemia and small lymphocytic or follicular lymphomas. Blood Lymphat Cancer. 2016;6:1–6. PubMedPubMedCentral
20.
Zurück zum Zitat Schötz U, Balzer V, Brandt F. Dual PI3K/mTOR-inhibitor NVP-BEZ235 enhances radiosensitivity in head and neck squamous cell carcinoma (HNSCC) cell lines due to suppressed double-strand break (DSB) repair by non-homologous end joining. Cancers. 2020;12(2):467. CrossRef Schötz U, Balzer V, Brandt F. Dual PI3K/mTOR-inhibitor NVP-BEZ235 enhances radiosensitivity in head and neck squamous cell carcinoma (HNSCC) cell lines due to suppressed double-strand break (DSB) repair by non-homologous end joining. Cancers. 2020;12(2):467. CrossRef
21.
Zurück zum Zitat Soulières D, Faivre S, Mesia R, et al. Buparlisib and paclitaxel in patients with platinum-Pretreated recurrent or metastatic squamous cell carcinoma of the head and neck (BERIL-1): a Randomised, double-blind, placebo-controlled phase 2 trial. Lancet Oncol. 2017;18(3):323–35. CrossRef Soulières D, Faivre S, Mesia R, et al. Buparlisib and paclitaxel in patients with platinum-Pretreated recurrent or metastatic squamous cell carcinoma of the head and neck (BERIL-1): a Randomised, double-blind, placebo-controlled phase 2 trial. Lancet Oncol. 2017;18(3):323–35. CrossRef
22.
Zurück zum Zitat Kim SJ, Jung KH, Son MK, et al. Tumor vessel normalization by the PI3K-inhibitor HS-173 enhances drug delivery. Cancer Lett. 2017;403:339–53. CrossRef Kim SJ, Jung KH, Son MK, et al. Tumor vessel normalization by the PI3K-inhibitor HS-173 enhances drug delivery. Cancer Lett. 2017;403:339–53. CrossRef
23.
Zurück zum Zitat Stausbol-Gron B, Overgaard J. Relationship between tumour cell in vitro radiosensitivity and clinical outcome after curative radiotherapy for squamous cell carcinoma of the head and neck. Radiother Oncol. 1999;50:47–55. CrossRef Stausbol-Gron B, Overgaard J. Relationship between tumour cell in vitro radiosensitivity and clinical outcome after curative radiotherapy for squamous cell carcinoma of the head and neck. Radiother Oncol. 1999;50:47–55. CrossRef
25.
Zurück zum Zitat Park JH, Jung KH, Kim SH, et al. Radiosensitization of the PI3K-Inhibitor of HS-173 through reduction of DNA damage repair in pancreatic cancer. Oncotarget. 2017;8(68):112893–906. CrossRef Park JH, Jung KH, Kim SH, et al. Radiosensitization of the PI3K-Inhibitor of HS-173 through reduction of DNA damage repair in pancreatic cancer. Oncotarget. 2017;8(68):112893–906. CrossRef
26.
Zurück zum Zitat Michmerhuizen NL, Leonard E, Kulkarni A, Brenner JD. Differential compensation mechanisms define resistance to PI3K inhibitors in PIK3CA amplified HNSCC. Otorhinolaryngol Head Neck Surg. 2016;1(2):44–50. CrossRef Michmerhuizen NL, Leonard E, Kulkarni A, Brenner JD. Differential compensation mechanisms define resistance to PI3K inhibitors in PIK3CA amplified HNSCC. Otorhinolaryngol Head Neck Surg. 2016;1(2):44–50. CrossRef
27.
Zurück zum Zitat Niehr F, Eder T, Pilz T, et al. Multilayered omics-based analysis of a head and neck cancer model of cisplatin resistance reveals intratumoral heterogeneity and treatment-induced clonal selection. Clin Cancer Res. 2018;14(1):158–68. CrossRef Niehr F, Eder T, Pilz T, et al. Multilayered omics-based analysis of a head and neck cancer model of cisplatin resistance reveals intratumoral heterogeneity and treatment-induced clonal selection. Clin Cancer Res. 2018;14(1):158–68. CrossRef
Metadaten
Titel
HS-173, a selective PI3K inhibitor, induces cell death in head and neck squamous cell carcinoma cell lines
verfasst von
MD Elisabeth Foki
MD Isabella Stanisz
MD Lorenz Kadletz
MD Ulana Kotowski
MD, DMD, MSc, MBA Rudolf Seemann
MD Rainer Schmid
MD, PD Gregor Heiduschka
Publikationsdatum
02.09.2020
Verlag
Springer Vienna
Erschienen in
Wiener klinische Wochenschrift / Ausgabe 1-2/2021
Print ISSN: 0043-5325
Elektronische ISSN: 1613-7671
DOI
https://doi.org/10.1007/s00508-020-01729-3

Weitere Artikel der Ausgabe 1-2/2021

Wiener klinische Wochenschrift 1-2/2021 Zur Ausgabe

mitteilungen der gesellschaft der ärzte in wien

Veranstaltungstipps

mitteilungen der gesellschaft

mitteilungen der gesellschaft